ARS Pharmaceuticals (SPRY) Q2 2026 Earnings Report

The call balanced encouraging commercial momentum and a clear strategic reset with notable operational and financial challenges. Positive indicators include doubled overall market share (2.5% to 5%), an 8% share in field-targeted accounts, triple+ growth in unique prescribers, a completed sales-force expansion, hiring of an experienced CCO, and a plan to reduce cash-based SG&A by over 40% in H2 with a stated path to cash-flow breakeven by end of 2027. Offsetting these positives are high Q2 operating expenses (~$95.1M), elevated SG&A (~$77.6M), gross-to-net pressure near ~50%, manufacturing/short-dated inventory impacts on margins, payer prior-authorization friction (only ~57% without PA) and a modest delay in the CSU Phase IIb interim readout to Q1 2027. Overall, the company presented a constructive corrective plan but material execution and margin risks remain.

Management guided to a disciplined, provider-focused plan with specific financial and commercial targets: Q2 total revenue was $33.7M, U.S. net product revenue $26.2M, total U.S. market share 5% (up from 2.5% YoY) and 8% within the field-targeted universe (up from 4% YoY), with >16,000 unique net prescribers in Q2 (3x YoY). Q2 gross margin was ~62% (YTD ~64%) with gross-to-net around ~50% expected to ebb and flow, and Q2 operating expenses totaled $95.1M (including $12.8M COGS) and ~ $77.6M SG&A for the quarter. For H2 2026 they guided aggregate SG&A and R&D of $114M–$126M (including stock-based comp of ~$14M–$60M), with cash-based SG&A and R&D of $100M–$110M (driven by >40% reduction in cash-based SG&A vs. H1 2026) and cash, cash equivalents and short‑term investments of $143.8M at quarter end; management expects this runway and spending posture to support a path to cash‑flow breakeven by end of 2027. They also noted 90% commercial coverage (57% without prior authorization), a sales focus on the 44% of the market representing highest‑value prescribers, and a modest delay of the CSU Phase IIb interim readout to Q1 2027.